Novavax, Inc. Aktie News

Shares for Novavax swelled by more than 140% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot for protecting against the flu and Covid.

Novavax will receive as much as $1.2 billion as part of a Covid vaccine licensing deal with Sanofi.

Novavax (NASDAQ: NVAX ) stock is on the rise Friday after the biotechnology company announced a deal with Sanofi (NASDAQ: SNY ) alongside its Q1 earnings report. The big news here is the two companies signing a co-exclusive licensing agreement.

The two companies will also work on a shot that combines Covid-19 and flu vaccines.

Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company's fiscal Q1 2024 earnings report but more significantly, by a crucial multi-billion dollar deal with French pharmaceutical giant Sanofi SA. Despite reporting a first-quarter loss per share of $1.05, wider than the $0.92 anticipated by analysts, and revenue of $93.

Novavax on Friday said it had struck a $1.4 billion deal with Sanofi to commercialize its existing COVID-19 vaccine and develop a new combined jab to inoculate against both the coronavirus and influenza, in a major boost to struggling biotech company.

COVID-19 vaccine maker Novavax , on Friday, erased doubts about its ability to remain in business by removing a so-called "going concern" notice.

Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvant This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including : $500 million upfront payment Approximately $70 million equity investment ...